Revenue: As of FY2025 Q1, the actual value is USD 2.878 B.EPS: As of FY2025 Q1, the actual value is USD 0.14.EBIT: As of FY2025 Q1, the actual value is USD 91.57 M.<h3>Pharmacy Solutions Segment</h3><ul><li>Revenue: $2,532.2 million for the three months ended March 31, 2025, compared to $1,977.0 million for the same period in 2024, an increase of $555.1 million or 28.1%.</li><li>Cost of Goods: $2,328.2 million for the three months ended March 31, 2025, compared to $1,807.1 million for the same period in 2024, an increase of $521.1 million or 28.8%.</li><li>Gross Profit: $204.0 million for the three months ended March 31, 2025, compared to $169.9 million for the same period in 2024, an increase of $34.0 million or 20.0%.</li><li>Selling, General, and Administrative Expenses: $115.7 million for the three months ended March 31, 2025, compared to $109.0 million for the same period in 2024, an increase of $6.7 million or 6.2%.</li><li>Segment EBITDA: $115.7 million for the three months ended March 31, 2025, compared to $88.2 million for the same period in 2024, an increase of $27.6 million or 31.2%.</li></ul><h3>Provider Services Segment</h3><ul><li>Revenue: $345.9 million for the three months ended March 31, 2025, compared to $308.8 million for the same period in 2024, an increase of $37.2 million or 12.1%.</li><li>Cost of Services: $211.5 million for the three months ended March 31, 2025, compared to $186.2 million for the same period in 2024, an increase of $25.4 million or 13.6%.</li><li>Gross Profit: $134.4 million for the three months ended March 31, 2025, compared to $122.6 million for the same period in 2024, an increase of $11.9 million or 9.7%.</li><li>Selling, General, and Administrative Expenses: $90.1 million for the three months ended March 31, 2025, compared to $81.5 million for the same period in 2024, an increase of $8.6 million or 10.5%.</li><li>Segment EBITDA: $51.1 million for the three months ended March 31, 2025, compared to $46.8 million for the same period in 2024, an increase of $4.3 million or 9.3%.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: BrightSpring Health Services plans to divest its Community Living business to focus on senior and specialty populations, aiming for increased strategic focus, operational efficiencies, and greater clinical integration across the Provider Services segment.</li><li>Non-Core Business: The divestiture of the Community Living business is expected to close in 2025, subject to customary closing conditions, and is anticipated to augment revenue and adjusted EBITDA growth rates.</li></ul>

BrightSpring Health Services - Unit | 10-Q: FY2025 Q1 Revenue: USD 2.878 B